---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014811"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:14:43.741626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised

## Summary
- Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).
- Core revenue (ex-COVID) $45.3M, +102% YoY; full-year core revenue guidance raised to $185M from $180M.
- GAAP net income $11.5M ($0.37/share); non-GAAP net income $24.3M ($0.78/share); adjusted EBITDA $37.7M.
- Cash & marketable securities $931M as of June 30, 2022.
- Strong growth in genetic testing beyond COVID driving core revenue expansion.

## SEC filing metadata
- accession: 0000950170-22-014811
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/0000950170-22-014811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/flgt-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014811
- JSON: https://secwatch.observer/filing/0000950170-22-014811.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.